Wegovy® (injection) and vomiting

Vomiting in the product information

Section 6.1 of the US label gives a separate table for each group of injection trials: an adult 2.4 mg pool (2,116 people on Wegovy®, 1,261 on placebo, up to 68 weeks), two 72-week high-dose trials with three arms, and a 68-week trial in young people aged 12 and older. ^[1] The EU product information pools STEP 1–4; the Canadian monograph pools STEP 1–3. ^[2][3]

Is it 24% or 25%?

Readers who check the US label may spot a small mismatch. Table 3 shows 24% for vomiting in adults on 2.4 mg, while the paragraph on digestive reactions further down gives 25% against 6%. ^[1] The EU figure of 24.5% sits between the two, so the difference is most likely rounding. This page uses the table value in the US rows.

The same paragraph sets the wider picture: 73% of adults on the injection and 47% on placebo reported at least one digestive reaction, most often during dose escalation. ^[1]

Timing, duration and the higher dose

All three documents put most digestive reactions in the dose-escalation weeks. ^[1][2][3] The injection climbs from 0.25 mg in four-week steps over 16 weeks, and the label lets a step be delayed by four weeks when a dose is not tolerated. ^[1] In the EU and Canadian data, most events were mild to moderate and short, and a vomiting episode lasted a median of 2 days. ^[2][3]

Vomiting rose with the higher strength: in the 7.2 mg trials, 22% on 7.2 mg reported it against 16% on 2.4 mg. ^[1] Moving to 7.2 mg is described only for adults who have tolerated 2.4 mg for at least four weeks, and the decision rests with the prescriber. ^[1]

A manufacturer-funded analysis of STEP 1–3 found that 98.1% of digestive events were mild to moderate, that they occurred mostly during or shortly after escalation, and that weight loss did not depend on having them. ^[4] A study of the US FDA voluntary reporting system found digestive reports for semaglutide tended to start in the first weeks, with risk appearing to fall over time; such reports cannot show how often vomiting happens or prove it was caused by the medicine. ^[5]

Why the teenage number stands out

In the adolescent trial, vomiting was the second most common reaction, close behind nausea at 42%. At 36% on the injection against 10% on placebo, the gap is wider than in either adult pool. ^[1] The label offers no explanation, and it would be guesswork to supply one. The trial enrolled 201 young people with obesity, average age about 15; 62% of those on Wegovy® and 42% on placebo had some digestive reaction, and 2.3% versus 1.5% stopped because of one. ^[1] The Canadian monograph notes that adolescents may stay on a lower dose if 2.4 mg cannot be reached or is not tolerated, a decision for their prescriber. ^[3]

Fluid loss, blood pressure and the kidneys

• Stopping treatment: in the adult 2.4 mg pool, vomiting led 1.2% of people on the injection to stop for good; nobody on placebo stopped for this reason. In the 7.2 mg trials, digestive reactions together led 3% of each Wegovy® arm and 0.3% of placebo to stop. ^[1]
• Kidneys: section 5.5 describes post-approval reports of acute kidney injury on semaglutide, some needing dialysis, mostly after digestive reactions had caused dehydration. Prescribers are asked to monitor kidney function in such people, especially at the start and during dose increases. ^[1]
• Blood pressure: in the adult weight trials, low-blood-pressure reactions were reported in 1.3% on Wegovy® and 0.4% on placebo, and fainting in 0.8% versus 0.2%; some were linked to digestive reactions and volume loss. ^[1]
• Overdose: the EU product information says an overdose of semaglutide may cause digestive disorders that can lead to dehydration. ^[2]

Other reasons for vomiting

MedlinePlus lists many everyday causes of vomiting beyond medicines: stomach bugs, food poisoning, reflux, migraine, pregnancy, motion sickness, severe pain such as from kidney stones and heavy cannabis use. It also warns that vomiting can be an early sign of appendicitis, a blocked bowel or an ulcer. ^[7] Two of these appear in the Wegovy® label: appendicitis occurred in 0.5% of adults on Wegovy® versus 0.2% on placebo, and ileus and intestinal obstruction are listed among post-approval reports. ^[1] Vomiting with severe belly pain or a swollen belly is not something to wait out.

Comfort steps and fluids

Novo Nordisk’s US patient page suggests talking with your healthcare professional about general steps such as eating more slowly, choosing bland, low-fat foods and foods that contain water, getting fresh air, and avoiding greasy food or lying down after meals; it also suggests asking how to stay hydrated without feeling too full. ^[6] MedlinePlus adds that drinking small amounts of clear liquids often is part of home care once the cause is known. ^[7]

MedlinePlus describes early dehydration as thirst, a dry or sticky mouth, passing little or darker urine, headache and muscle cramps; dizziness, confusion and a fast heartbeat point to more severe dehydration. ^[8] The Wegovy® label does not address anti-sickness medicines and asks you to tell your provider about everything you take, including over-the-counter products. ^[1] Before a planned operation or sedation, tell every provider involved that you use Wegovy®, because it slows stomach emptying. ^[1]

Wegovy® is a registered trademark of Novo Nordisk A/S. PepLabo is not affiliated with or endorsed by Novo Nordisk.

When to get help